J&J Sets The Pace In Race To $10bn RSV Vaccine Market

80% Efficacy Against Severe Disease In 65+ Group

Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.

Janssen Pharmaceutica sign and logo
GSK and Pfizer have already begun Phase III studies, but J&J's Phase II results are the most compelling so far.

Johnson & Johnson has unveiled new data from its respiratory syncytial virus (RSV) vaccine showing 80% protection against severe infection in over 65s - setting a high benchmark for rivals such as Pfizer and GlaxoSmithKline in what is forecast to become a $10bn market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By 

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By 

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By 

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.